Top Four Trials From TCT 2024: EARLY TAVR, TRISCEND II, ECLIPSE, and CLEAR SYNERGY (OASIS 9)
In this special edition of Eagle’s Eye View, Dr. Eagle looks four of the most important trials presented at the recent TCT Conference: 1) EARLY TAVR evaluating TAVR compared to clinical surveillance; 2) TRISCEND II looking at the Evoque transcatheter tricuspid valve replacement (TTVR) system for severe tricuspid regurgitation; 3) ECLIPSE evaluating orbital atherectomy prior to drug-eluting stent implant compared to conventional PCI; and 4) CLEAR SYNERGY (OASIS 9) assessing the effects of colchicine after PCI for a STEMI or large NSTEMI.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Aortic Surgery, Cardiac Surgery and VHD, Interventions and Structural Heart Disease
Keywords: EaglesEyeView, Atherectomy, Colchicine, Heart Valve Diseases, Percutaneous Coronary Intervention, TCT24, Transcatheter Aortic Valve Replacement, Transcatheter Cardiovascular Therapeutics, Tricuspid Valve
